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Purpose of the study
Diabetes mellitus (DM) is a major risk factor for cardio-
vascular disease (CVD) among the general population,
and a strong risk factor for CVD in the HIV-infected pop-
ulation. Prediction models for the onset of type II DM in
the general population have been developed but have not
yet been validated amongst HIV-infected individuals. Our
objective is to develop a risk assessment model for the
short-term risk of DM for HIV-infected populations fol-
lowing the commencement of combination therapy.
Methods
All patients recruited to D:A:D with follow-up data, with-
out prior DM or MI or other CVD events, and with a com-
plete DM risk factor profile were included. Baseline was
defined as the first time point at or after inclusion to the
D:A:D study when information on all DM risk factors was
available. Data were randomly split, into a training (66%)
and validation (34%) data sets. A D:A:D predictive model
for the short-term risk of DM was determined in the train-
ing dataset using Poisson regression methods. Expected 8-
year probabilities of DM events were also determined
based on the Framingham Offspring Study DM algorithm,
and subsequently converted to predict over the shorter
D:A:D follow-up. The D:A:D and the Framingham models
were then assessed in the validation dataset. Area under
the receiver operating characteristic (AROC) curve and
predicted vs. observed events were determined for the
D:A:D and recalibrated Framingham models.
Summary of results
13,609 patients had a complete risk factor profile; 251
cases of new onset DM occurred during 50,296 person-
years. Median follow-up was 3.50 years (IQR: 1.36–6.16).
The training dataset included 8,990 patients with 170
cases of new onset DM, and the validation dataset
included 4,619 patients with 81 cases of DM. Factors pre-
dictive of DM in the D:A:D study included: higher glucose,
BMI and triglyceride levels, older age, lower HDL and
injecting drug use as reported mode of HIV exposure. The
performance of the D:A:D and Framingham equations in
the validation dataset yielded the following AROC: 0.80
(95% CI:0.75, 0.85); and 0.77 (95% CI:0.71, 0.83). The
Framingham algorithm over predicted DM events com-
pared to the D:A:D model for younger age (observed (O)
= 19, predicted D:A:D (PD) = 18, predicted Framingham
(PF) = 310, lower BMI (O = 40, PD = 39, PF = 49), and
lower glucose (O = 48, PD = 45, PF = 61).
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The D:A:D equation performed well in predicting the
short-term of DM in the validation dataset, and for spe-
cific subgroups fared better than the Framingham algo-
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